Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00235053|
Recruitment Status : Unknown
Verified September 2005 by Allergy & Asthma Medical Group & Research Center.
Recruitment status was: Active, not recruiting
First Posted : October 10, 2005
Last Update Posted : January 31, 2006
|Condition or disease||Intervention/treatment||Phase|
|Asthma Candidiasis, Oral Voice Disorders||Drug: fluticasone/salmeterol DISKUS 250/50||Phase 4|
Asthma is a chronic inflammatory disorder of the airways. The inflammation is associated with bronchial hyperresponsiveness, airflow obstruction, and respiratory symptoms including wheezing, coughing and chest tightness.
Inhaled corticosteroids are the most effective controller asthma medications. They are indicated for management of persistent asthma at all levels of severity. They have been documented to improve symptoms and pulmonary function and reduce exacerbations, need for quick-relief medications and airway hyperresponsiveness.
Despite their benefits, inhaled corticosteroids have been associated with adverse local effects. These include oral candidiasis and dysphonia. However, though these risks have been reported, they have not been carefully studied. The incidence of oral candidiasis in newly treated subjects and its onset within a carefully monitored timeframe have not been adequately assessed.
A more overtly undesirable effect is dysphonia. Data on it are usually collected from spontaneous reports by patients in clinical trials. However, awareness of dysphonia requires a certain degree of subjective discomfort to initiate the report. Subjective awareness of dysphonia often varies based on an individuals voice requirements. A singer, for example, is usually acutely aware of minor voice changes in contrast to someone who does not depend on voice quality. Nonetheless, voice abnormalities can probably occur with similar frequency in patients who are concerned or not concerned with their voice due to inhaled corticosteroids. New subjective scales for reporting on an individual’s voice have recently been validated and published in other areas. These scales have not been validated in patients with asthma or in subjects using inhaled corticosteroids. New technologies for objective voice assessment have also been developed and these permit greater ability to quantify voice changes. These advances permit better measures of the potential adverse effects of inhaled corticosteroids on voice both with regard to onset of abnormalities and with regard to magnitude of effects.
This pilot study is an initial probe into clarifying the potential of the inhaled corticosteroid, fluticasone propionate delivered in the Advair DISKUS device to produce oral candidiasis and voice changes, and to determine the best measurement to quantitate objectively that effect.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||13 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma|
|Study Start Date :||August 2005|
|Study Completion Date :||November 2005|
- To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma.
- 1. Voice Related Quality of Life (VRQOL)
- 2. Inhaled Corticosteroid Questionnaire (ICQ)
- 3. Reflux Symptom Index (RSI)
- 4. Videostroboscopy and Determination of Reflux Finding Score (RFS)
- 5. Voice jitter
- 6. Voice shimmer
- 7. Signal to noise ratio
- 8. Oropharyngeal Candida species culture
- 9. Oropharyngeal Candida species related symptoms
- 10. Oropharyngeal thrush on physical exam
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00235053
|United States, California|
|Allergy & Asthma Medical Group & Research Center|
|San Diego, California, United States, 92123|
|Principal Investigator:||Eli O Meltzer, MD||Allergy & Asthma Medical Group & Research Center|